Evaluating the effectiveness of FOLFIRINOX chemotherapy in pancreatic cancer patients after surgery
A Long-term Follow-up Study of FOLFIRINOX Regimen as Adjuvant Therapy in Pancreatic Cancer Patients After Curative Surgery: Multi-center, Prospective
This study is testing if the FOLFIRINOX chemotherapy helps pancreatic cancer patients who have had surgery live longer and stay cancer-free.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 36 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | HK inno.N Corporation Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06389552 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the long-term outcomes of patients with pancreatic cancer who receive the FOLFIRINOX regimen as adjuvant therapy following curative surgery. It is a multi-center, prospective study that will follow participants over an extended period to evaluate disease-free survival (DFS) and overall survival (OS). The study will include patients who meet specific eligibility criteria, ensuring a focused approach to understanding the treatment's efficacy in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 19 years old who are planning to receive FOLFIRINOX as adjuvant therapy after undergoing surgery for pancreatic cancer.
Not a fit: Patients who have contraindications to FOLFIRINOX or those receiving palliative therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of FOLFIRINOX in improving survival rates for pancreatic cancer patients post-surgery.
How similar studies have performed: Other studies have shown promising results with FOLFIRINOX in similar contexts, indicating a potential for success in this observational study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age over 19 at the time of obtaining the informed consent form * Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery * ECOG 0 or 1 * Scheduled to RO or R1 resection * Organ function capable of chemotherapy Exclusion Criteria: * FOLFIRINOX contraindications among the drug approval requirements * Palliative Therapy * Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX
Where this trial is running
Seoul
- Seoul ST. Mary's Hospital — Seoul, South Korea (Recruiting)
Study contacts
- Study coordinator: Soyeon Ahn
- Email: soyeon.ahn@inno-n.com
- Phone: 82-2-6477-0252
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.